GALT — Galectin Therapeutics Share News
0.000.00%
Last trade - 00:00- $340.87m
- $465.30m
Brief: Galectin Therapeutics Reports Quarterly Loss Per Share Of $0.15
Galectin Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Galectin Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Galectin Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Galectin Therapeutics jumps on upbeat early-stage study data on cancer drug
Brief: Galectin Therapeutics Announces Positive Top-Line Results From Phase 1B Trial Extension Of Belapectin In Combination With Keytruda®
Galectin Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Galectin Therapeutics Inc - As Of March 31, 2021, Had $20.8 Mln Of Cash And Cash Equivalents
Galectin Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Galectin Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Galectin Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant
U.S. STOCKS ON THE MOVE-American Airlines, ATyr, Exact Sciences, SOS
U.S. STOCKS ON THE MOVE-Discovery, Nikola, Moderna, Galectin
Galectin: Soars on data showing lead drug's potential in cancer treatment
U.S. STOCKS ON THE MOVE-FibroGen, Sos Ltd, Ebang, CA Healthcare
Brief: Galectin Therapeutics Reports Fiscal 2020 Financial Results And Provides Business Update
Brief: Oncoimmunology Publishes Pre-Clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor
Brief: Galectin Therapeutics Inc Says Joel Lewis Assumes CEO Role